Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Full Data For Intercept's Liver Disease Drug Show Rivals Where To Differentiate

Executive Summary

Full Phase III data for Intercept Pharmaceuticals Inc.'s recently approved rare liver disease drug, Ocaliva, have highlighted potential treatment gaps for upcoming pipeline drugs, including candidates from Gilead Sciences Inc., Novartis AG, Shire Pharmaceuticals plc and GlaxoSmithKline plc.

Advertisement

Related Content

Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Intercept Seeks Long-Term Data To Build Ocaliva Market In PBC
The NASH Pipeline: Replete With Targets And New Compounds
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel